Loading...
TFFP logo

TFF Pharmaceuticals, Inc.NasdaqCM:TFFP Rapporto sulle azioni

Cap. di mercato US$288.8k
Prezzo delle azioni
n/a
Il mio valore equo
Non disponibile
1Y-99.2%
7D-77.6%
1D
Valore del portafoglio
​
Vista

TFF Pharmaceuticals, Inc.

Report azionario NasdaqCM:TFFP

Capitalizzazione di mercato: US$288.8k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

TFF Pharmaceuticals (TFFP) Panoramica del titolo

TFF Pharmaceuticals, Inc. è una società biofarmaceutica in fase clinica che si concentra sullo sviluppo e la commercializzazione di prodotti farmaceutici basati sulla sua piattaforma tecnologica brevettata di congelamento a film sottile (TFF) negli Stati Uniti e in Australia. Maggiori dettagli

TFFP analisi fondamentale
Punteggio fiocco di neve
Valutazione2/6
Crescita futura0/6
Prestazioni passate0/6
Salute finanziaria3/6
Dividendi0/6

Premi

Gli utili sono cresciuti del 6% all'anno negli ultimi 5 anni

Analisi del rischio

Non ha una capitalizzazione di mercato significativa ( $289K )

Ha meno di 1 anno di pista di cassa

Prezzo delle azioni altamente volatile negli ultimi 3 mesi rispetto al mercato US

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

+ 1 più rischio

TFFP Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Concorrenti di TFF Pharmaceuticals, Inc.

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per TFF Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$0.065
Massimo di 52 settimaneUS$11.00
Minimo di 52 settimaneUS$0.061
Beta1.06
Variazione di 1 mese-82.72%
Variazione a 3 mesi-97.03%
Variazione di 1 anno-99.17%
Variazione a 3 anni-99.97%
Variazione a 5 anni-99.94%
Variazione dall'IPO-99.95%

Notizie e aggiornamenti recenti

Recent updates

Articolo di analisi • Apr 10

Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Articolo di analisi • Sep 27

Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Aug 29

TFF Pharma: The Potential Is Still Very Much Present

Summary While the company added three more big pharma partners, this is not what shareholders prefer to hear as the company already has more than two dozen of these. These partnerships are mostly in the pre-clinical phase and are unlikely to lead to near-time monetization. For monetization, there are four near-time candidates, Voriconozale and Tacrolimus look to be the most certain candidates but PLUS (cannabis) and UNION (Niclosamide) are additional deal candidates. A deal is necessary as cash levels are getting low, which might necessitate earlier partnering and forfeiting some future revenue. But just one deal with upfront payments is likely to considerably improve their situation so the stock remains very interesting. TFF Pharma (TFFP) has a unique platform, Thin Film Freezing, to turn drugs into an inhalable form which produces a host of benefits: Many drugs are not well absorbed orally, for instance, because they don't dissolve in water. An inhalable form bypasses digestion which enables much lower dosages with lower toxicity, side effects and possible drug-drug interactions. They also bring the drug directly to affected areas in case of lung and airway problems (or pathway for the line of attack, as in the case of airborne viruses). Dry powder form greatly extends the shelf-life of drugs and vaccines and bypasses cold-chain storage of some vaccines. Management also claims their TFF platform is better than alternative forms of dry powder inhalable formulation techniques: TFFP IR presentation The company's specialists recently published a scientific paper (written by the co-inventor of Thin Film Freezing, Bill Williams, Improved Formulations to Enable Stable Delivery of Biologics published in BioPharm International) buttressing the advantages of TFF over other dry powder formulations, in short summary: Dry-freezing leads to aggregation in many cases which can negatively impact bioactivity. TFF formulations don't suffer from this. TFF formulations don't suffer from this. Many biologics are vulnerable and cannot withstand the impact of shear and stress or elevated temperatures during the drying process. TFF formulations don't suffer from this. TFF dry powder formulations preserve bioactivity until 40 degrees Celcius, eliminating cold-chain distribution and storage (which led to $1B+ of Covid vaccine destruction recently). This also holds for vaccines containing the MF59 adjuvant (which require refrigerated storage, but not in TFF powder form). Vaccines with MF59 are also sensitive to accidental slow freeze conditions, which TFF formulations obfuscate. TFF formulations of vaccines and drugs for respiratory illnesses seem particularly promising and management argues that they are working with a number of vaccine producers, but they have said so for quite some time Yet despite all these compelling benefits it is one of our more frustrating holdings. There is so much potential, and so many possible use cases and partnerships, but nearly all of the progress is made at the pre-clinical stage where they continue to add drug candidates and pharma partners, many of which we discussed in previous articles (see here and here). It is true that these involve reformulations for already approved drugs and therefore the reduced 50((B))(2) regulatory pathway is not as taxing but this still is a matter of years rather than months but investors hoped that there would be more progress on the monetization front by now. Business model TFFP IR presentation The internal development program produces TFF dry powder form of drugs for which patents are expired and the costs are born by TFF Pharma, but at some stage, partnerships are sought to share the clinical trial cost. The company has four internal development programs (Tacrolimus, Voriconazole, Niclosamide, and Augmenta 3378, an inhaled form of monoclonal antibodies) with Vori and Tac in stage 2 clinical trials as the most advanced of these. Both drugs have significant market opportunities, here is Tacrolimus TFFP IR presentation And for Voriconazole: TFFP IR presentation The both have phase 2 results expected in Q3 and the idea is that management will look for partnerships (Q2CC): As previously discussed, we intend to partner these programs and we're currently working with Torreya Partners to reach out broadly to potential interested companies. This would bring urgently needed revenues with the company sitting on just $20.9M of cash and cash equivalents, which won't last them even a year. UNION Therapeutics could also offer a deal as the results from the phase 1 Niclosamide study were positive and the Covid situation looks to scream for a product like this, from the Q2CC: And many of the patients that die are in high risk categories, cancer patients, patients who can't take Paxlovid due to drug-drug interactions. And we think that those patients will benefit from inhaled Niclosamide because they're -- again like Voriconazole when we deliver to the lung, you can avoid drug-drug interactions. And we've also seen that from the Paxlovid rebound, it's very clear that BA.5 and potentially future variants will take longer. UNION has an option for worldwide licensing which is likely to contain at least some upfront payment. To give you some idea of the possible sums involved, from the linked PR: Under the agreement, UNION will pay TFF up to 210 million USD related to option exercise, development and commercial milestones, as well as tiered single-digit royalties on product sales. Management proposed a sort of new model going forward based on the Augmenta 3387 monoclonal antibodies deal (Q2CC): Augmenta, we were going to take through Phase 1 and still might, and then split proceeds from that point on. So we have a number of different options available to us as we seek to -- we kind of refresh and serially look at taking products through the pipeline. In general, Jonathan, it takes about $7 million to $12 million depending on the cost of the API to get us to that inflection point. It seems like a reasonable cost-saving way to shift the internal development projects once these are taken to their inflection points with monetization deals in place. However, there is a trade-off as future revenues will be lower the earlier a project is shared with commercial partners. This new handing over after phase 1 trials are completed might have a direct impact on the situation with UNION and TFF formulations of Niclosamide. On slide 23 of their August 2022 IR presentation there was a footnote that Niclosamide would begin phase 2 trials in Q3/22 with the proviso that it would transition to UNION. It wasn't all that long ago that the Roth had a 12 month price target of $27 based on 4x 2030 operating income of $195M from royalties (Vori, Tac and cannabis, so plenty of upside from other programs). If these royalties are lower because partners assume cost of development then this is at the detriment of their long-term revenue perspective, but it looks like the company has little choice. Partnerships The company isn't just dependent on their own development work, they partner with a host of pharma companies from the start as well. The company has over two dozen partnerships with pharma companies to produce dry powder form for one or more of their drugs and continues almost every quarter to add to these. They did so again and gained 3 more top-20 pharma partners in Q2, which is of course significant but not leading to any immediate revenue generation as these are almost certainly early-stage pre-clinical lab-bound formulation agreements.
Seeking Alpha • Aug 09

TFF Pharmaceuticals: Q3 Data Is Pivotal In So Many Ways

Once promising, TFF Pharma is now cash-strapped and stagnant. TFFP badly needs some good news. Q3 interim data may provide that. TFF Pharmaceuticals (TFFP) works with a novel method of producing dry powder formulation of known drugs. Licensed from UT Austin and initially developed by Dow, this technology has advantages over the two other known dry powder formulation technologies. Like I noted before: There are competing and time-tested methods of producing dry powder formulations of medicines. Spray drying, which uses heat to cause evaporation, is one - however, this method does not produce adequate porosity for deep lung delivery. Lyophilization is a slower method which does, but it increases risks of molecular degradation and contamination. TFF overcomes the inadequacies of both methods, producing dry powder drugs 100x to 1000x faster than the latter method, and enables deep lung delivery of known-efficacy common drugs. I covered TFFP thrice last year, and the stock has been something of a laggard, mainly, I suspect, due to a data desert. Today, the company has two programs in phase 2 - TFF Vori for Invasive pulmonary aspergillosis ((IPA)) and TFF-TAC-LAC for the prophylactic treatment of lung transplant rejection. Other programs are in earlier phases. Both these projects completed phase 1 proof of concept trials last year. Phase 2 is ongoing; interim analysis is due in 2H 2022. Voricanozole is already approved to treat aspergillosis in patients 12 years or older. However, the drug comes with significant side effects and loss of function due to the inefficient mode of delivery. An alternative to vori is Oral and IV amphotericin; TFF-Vori has shown 3x better survival than amphotericin in IPA. It is also able to address the disease in children as young as 2 - a result of its better safety profile, doubtless. The company states that "dosages up to 80mg twice daily showed no signs of the clinically significant hepatic or visual toxicities previously reported for the oral or intravenous forms." As the company also says, Voricanozole comes with a long list of liver and visual toxicities: Hepatic toxicity, including clinical hepatitis, cholestasis and fulminant hepatic failure, including fatalities Visual disturbances, including optic neuritis and papilledema Other research I accessed says: Voriconazole use has increased since the drug's introduction in 2002, and new and unique adverse effects are emerging as patients undergo prolonged therapy. Most concerning is the increased risk of cutaneous malignancies, primarily squamous cell carcinoma ((SCC)); this risk is duration dependent and the associated malignancies tend to be more aggressive and multifocal. Voriconazole is also associated with phototoxicity (which may be a precursor to malignancy), periostitis, hallucinations and encephalopathy, peripheral neuropathy, alopecia, nail changes, hyponatremia, and other adverse effects. Some toxicities (neuropsychiatric and gastrointestinal including hepatic) are seen in clear association with supratherapeutic serum voriconazole levels… So it is noteworthy that treatment with TFFP's version of voriconazole did not elicit such adverse responses in patients as of now. However, this is also a matter of concern, going forward. As earlier research with inhaled vori has noted: Inhaled voriconazole reduces histological manifestations of invasive aspergillosis in rodents [3] and it has been proposed that a favourable lung tissue to plasma concentration ratio is obtained through this route of administration [4]. Consequently, inhaled voriconazole may provide higher concentrations at the site of infection without increasing the risk of systemic side-effects. The above cited research produces another cause of concern, one that I have dwelt on earlier in my TFFP coverage. The company needs to be cautious with its intellectual property. They have patents running to 2035, and they have a certain trade secret about the particular cooling temperature - these are the two competitive barriers they have available. However, inhaled vori has been used before - and although their particular method of dry powder formulation is likely novel, I suspect a successful approval will attract generic drugmakers and IP lawsuits.
Seeking Alpha • Jul 14

TFF Pharmaceuticals expands R&D operations with new Austin facility

TFF Pharmaceuticals (NASDAQ:TFFP) has announced a significant expansion of its R&D operations through the lease of a new research and development facility located in Austin, Texas. As TFF expands its in-house and partnered research, including applications in biologics, the additional laboratory space will also provide significantly more real estate to accommodate larger equipment to facilitate scale-up and manufacturing. The Co. also plans to expand the product development team in Austin, which will be based at the new facility, to support the growing number of partnered projects. “As our internal programs advance and our network of partnerships expands, establishing this additional research space in Austin is a natural next step,” added Glenn Mattes, CEO of TFF Pharmaceuticals.
Seeking Alpha • May 23

TFF Pharmaceuticals: A Highly Attractive Basket Of Options

TFFP is a platform company with leading technology. Clinical/FDA risk is extremely low. The stock is drastically undervalued based on only fraction of the pipeline and multiples of upside. Multiple insider purchases support the bull case and timing.

Rendimenti per gli azionisti

TFFPUS PharmaceuticalsUS Mercato
7D-77.6%3.6%1.3%
1Y-99.2%43.9%27.7%

Ritorno vs Industria: TFFP ha avuto una performance inferiore rispetto al US Pharmaceuticals che ha registrato un rendimento 43.9 % nell'ultimo anno.

Rendimento vs Mercato: TFFP ha avuto una performance inferiore al mercato US che ha registrato un rendimento 27.7 % nell'ultimo anno.

Volatilità dei prezzi

Is TFFP's price volatile compared to industry and market?
TFFP volatility
TFFP Average Weekly Movement34.0%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di TFFP è stato volatile rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale di TFFP è aumentata da 23% a 34% nell'ultimo anno.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
201819Craig Jalberttffpharma.com

TFF Pharmaceuticals, Inc. è una società biofarmaceutica in fase clinica che si occupa dello sviluppo e della commercializzazione di prodotti farmaceutici basati sulla sua piattaforma tecnologica brevettata Thin Film Freezing (TFF) negli Stati Uniti e in Australia. L'azienda intende concentrarsi sullo sviluppo di farmaci in polvere secca per via inalatoria per il trattamento di patologie e condizioni polmonari. I farmaci candidati sono TFF Voriconazole Inhalation Powder, in fase II di sperimentazione clinica per il trattamento e la profilassi dell'aspergillosi polmonare invasiva, e TFF Tacrolimus Inhalation Powder, in fase II di sperimentazione clinica per la prevenzione del rigetto del trapianto polmonare.

TFF Pharmaceuticals, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di TFF Pharmaceuticals con la sua capitalizzazione di mercato?
TFFP statistiche fondamentali
Capitalizzazione di mercatoUS$288.80k
Utili (TTM)-US$18.52m
Ricavi(TTM)US$1.16m
0.2x
Rapporto P/S
0.0x
Rapporto P/E

TFFP è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
TFFP Conto economico (TTM)
RicaviUS$1.16m
Costo del fatturatoUS$10.70m
Profitto lordo-US$9.54m
Altre speseUS$8.98m
Utili-US$18.52m

Ultimi utili riportati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)-4.17
Margine lordo-821.41%
Margine di profitto netto-1,595.04%
Rapporto debito/patrimonio netto0%

Come si è comportato TFFP nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2024/12/15 21:53
Prezzo dell'azione a fine giornata2024/12/12 00:00
Utili2024/09/30
Utili annuali2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

TFF Pharmaceuticals, Inc. è coperta da 4 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Mayank MamtaniB. Riley Securities, Inc.
Raghuram SelvarajuH.C. Wainwright & Co.
Jason McCarthyMaxim Group